KR20030047907A - 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 - Google Patents

말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 Download PDF

Info

Publication number: KR20030047907A
Authority: KR; South Korea
Prior art keywords: diabetic; peripheral; cgmp pde5; treating; pde5 inhibitor
Prior art date: 2000-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020027017948A

Other languages

English (en)

Korean (ko)

Inventor

랄프 이. 우드

Original Assignee

화이자 인코포레이티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2001-06-29

Publication date

2003-06-18

2001-06-29 Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드

2003-06-18 Publication of KR20030047907A publication Critical patent/KR20030047907A/ko

Status Ceased legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 15
208000018262 Peripheral vascular disease Diseases 0.000 title claims abstract description 14
208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 12
206010061666 Autonomic neuropathy Diseases 0.000 title claims abstract description 9
208000027232 peripheral nervous system disease Diseases 0.000 title 1
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 37
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims abstract description 29
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract description 19
239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract description 19
229960003310 sildenafil Drugs 0.000 claims abstract description 18
208000008960 Diabetic foot Diseases 0.000 claims abstract description 13
201000002829 CREST Syndrome Diseases 0.000 claims abstract description 5
206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 5
208000012322 Raynaud phenomenon Diseases 0.000 claims abstract description 5
208000025747 Rheumatic disease Diseases 0.000 claims abstract description 5
206010025135 lupus erythematosus Diseases 0.000 claims abstract description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 25
201000010099 disease Diseases 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
208000003790 Foot Ulcer Diseases 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 7
208000002474 Tinea Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
238000011161 development Methods 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229940124597 therapeutic agent Drugs 0.000 claims description 2
241000130764 Tinea Species 0.000 claims 1
206010002383 Angina Pectoris Diseases 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
238000011282 treatment Methods 0.000 description 30
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
150000001875 compounds Chemical class 0.000 description 17
208000010228 Erectile Dysfunction Diseases 0.000 description 12
201000001881 impotence Diseases 0.000 description 12
230000017531 blood circulation Effects 0.000 description 8
-1 2-ethoxy-5-morpholinoacetylphenyl Chemical group 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
206010056340 Diabetic ulcer Diseases 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
210000003141 lower extremity Anatomy 0.000 description 5
201000001119 neuropathy Diseases 0.000 description 5
230000007823 neuropathy Effects 0.000 description 5
208000012902 Nervous system disease Diseases 0.000 description 4
208000025966 Neurological disease Diseases 0.000 description 4
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
208000028867 ischemia Diseases 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000002792 vascular Effects 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010017533 Fungal infection Diseases 0.000 description 3
206010054805 Macroangiopathy Diseases 0.000 description 3
208000031888 Mycoses Diseases 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010040943 Skin Ulcer Diseases 0.000 description 2
241000893966 Trichophyton verrucosum Species 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000035876 healing Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
BRBNVIXMODBSND-UHFFFAOYSA-N 1-methyl-5-[5-(2-morpholin-4-ylacetyl)-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C=3N(C)N=C(CCC)C=3N=2)C(OCCC)=CC=C1C(=O)CN1CCOCC1 BRBNVIXMODBSND-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
GFVZTCIYHIUUJO-UHFFFAOYSA-N 5-[2-ethoxy-5-(1-methylimidazol-2-yl)phenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1C1=NC=CN1C GFVZTCIYHIUUJO-UHFFFAOYSA-N 0.000 description 1
OJECJYBJIYAQBH-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-propan-2-ylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C(C)C)CC1 OJECJYBJIYAQBH-UHFFFAOYSA-N 0.000 description 1
DDQVAJSWFPJSGC-UHFFFAOYSA-N 5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CCO)CC1 DDQVAJSWFPJSGC-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000010195 Onychomycosis Diseases 0.000 description 1
206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000003222 cGMP degradation Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000008242 dietary patterns Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
238000011542 limb amputation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000008338 local blood flow Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000007830 nerve conduction Effects 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 1
WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical compound O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
229960002639 sildenafil citrate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000006496 vascular abnormality Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
229940094720 viagra Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

KR1020027017948A 2000-06-30 2001-06-29 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 Ceased KR20030047907A (ko)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US21506500P	2000-06-30	2000-06-30
US60/215,065		2000-06-30
US21902900P	2000-07-18	2000-07-18
US60/219,029		2000-07-18

Publications (1)

Publication Number	Publication Date
KR20030047907A true KR20030047907A (ko)	2003-06-18

Family

ID=26909649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020027017948A Ceased KR20030047907A (ko)	2000-06-30	2001-06-29	말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법

Country Status (13)

Country	Link
EP (1)	EP1303279A1 (fr)
JP (1)	JP2004511433A (fr)
KR (1)	KR20030047907A (fr)
CN (1)	CN1440287A (fr)
AU (1)	AU2001279275A1 (fr)
BR (1)	BR0112100A (fr)
CA (1)	CA2414352A1 (fr)
HU (1)	HUP0301451A3 (fr)
IL (1)	IL153426A0 (fr)
MX (1)	MXPA03000033A (fr)
NZ (1)	NZ523108A (fr)
PL (1)	PL365565A1 (fr)
WO (1)	WO2002002118A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0020588D0 (en) *	2000-08-21	2000-10-11	Pfizer Ltd	Treatment of wounds
US8133903B2 (en)	2003-10-21	2012-03-13	Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center	Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
MXPA05009242A (es) *	2003-03-17	2006-04-18	Pfizer Prod Inc	Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
FR2877013A1 (fr) *	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2006074443A2 (fr) *	2005-01-07	2006-07-13	The Johns Hopkins University	Compositions d'inhibiteur des pde5 et procedes pour l'immunotherapie
MX2017016930A (es) *	2017-12-19	2019-06-20	Malesil Research & Tech Llc	Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6043252A (en) *	1997-05-05	2000-03-28	Icos Corporation	Carboline derivatives
US6075028A (en) *	1999-09-23	2000-06-13	Graham; Richard	Method of treating Tourette's syndrome and related CNS disorders

2001
- 2001-06-29 CN CN01812103A patent/CN1440287A/zh active Pending
- 2001-06-29 JP JP2002506740A patent/JP2004511433A/ja active Pending
- 2001-06-29 HU HU0301451A patent/HUP0301451A3/hu unknown
- 2001-06-29 IL IL15342601A patent/IL153426A0/xx unknown
- 2001-06-29 CA CA002414352A patent/CA2414352A1/fr not_active Abandoned
- 2001-06-29 KR KR1020027017948A patent/KR20030047907A/ko not_active Ceased
- 2001-06-29 MX MXPA03000033A patent/MXPA03000033A/es unknown
- 2001-06-29 PL PL01365565A patent/PL365565A1/xx not_active Application Discontinuation
- 2001-06-29 EP EP01957540A patent/EP1303279A1/fr not_active Withdrawn
- 2001-06-29 WO PCT/US2001/041202 patent/WO2002002118A1/fr not_active Ceased
- 2001-06-29 AU AU2001279275A patent/AU2001279275A1/en not_active Abandoned
- 2001-06-29 BR BR0112100-6A patent/BR0112100A/pt not_active IP Right Cessation
- 2001-06-29 NZ NZ523108A patent/NZ523108A/en unknown

Also Published As

Publication number	Publication date
MXPA03000033A (es)	2003-09-25
HUP0301451A2 (hu)	2003-09-29
WO2002002118A1 (fr)	2002-01-10
CA2414352A1 (fr)	2002-01-10
EP1303279A1 (fr)	2003-04-23
PL365565A1 (en)	2005-01-10
HUP0301451A3 (en)	2004-10-28
AU2001279275A1 (en)	2002-01-14
BR0112100A (pt)	2003-05-20
CN1440287A (zh)	2003-09-03
IL153426A0 (en)	2003-07-06
JP2004511433A (ja)	2004-04-15
NZ523108A (en)	2005-04-29

Publication	Publication Date	Title
TWI248816B (en)	2006-02-11	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
EP1303304B1 (fr)	2008-07-09	Combinaisons pharmaceutiques pour traiter et prevenir diabetes mellitus
KR100479968B1 (ko)	2005-03-30	위장 리파아제 억제제의 용도
CA2587391A1 (fr)	2006-05-26	Compositions utiles pour le traitement de maladies neovasculaires oculaires et la degenerescence maculaire
US6498193B2 (en)	2002-12-24	Treatment for complications of type 2 diabetes
CN101180062A (zh)	2008-05-14	防治糖尿病的复方制剂
CZ344498A3 (cs)	1999-04-14	Farmaceutická kompozice a způsob pro léčení velkých ztrát krve a pro inhibici nebo léčení hemorrhagického šoku
KR20030047907A (ko)	2003-06-18	말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법
RU2543635C2 (ru)	2015-03-10	Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
US20040176387A1 (en)	2004-09-09	Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
CN1213747C (zh)	2005-08-10	爱滋病特效药
EP1581195B1 (fr)	2010-05-26	Comprimes enrobes par un film comprenant un extrait de feuilles de vigne rouges
CN1350455A (zh)	2002-05-22	维生素联合应用治疗搔痒症和涉及搔痒和/或炎症的非感染性疾病
HK1055893A (en)	2004-01-30	Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
AU2002220960A1 (en)	2002-08-22	Regeneration of blood vessels
EP1372629A2 (fr)	2004-01-02	Traitement therapeutique
ZA200300015B (en)	2004-02-04	Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies.
CN106902115A (zh)	2017-06-30	阿哌沙班在治疗糖尿病足药物中的应用
RU2465896C2 (ru)	2012-11-10	Фармацевтическая противодиабетическая композиция пролонгированного действия
RU2564907C1 (ru)	2015-10-10	Способ лечения больных красным плоским лишаем
CA2412213C (fr)	2009-04-14	Procede pour traiter le choc septique
JPS6277318A (ja)	1987-04-09	熱傷治療剤
KR20030022352A (ko)	2003-03-15	일차성 두통의 치료에서 비타민 혼합물의 용도
Fotiu et al.	1974	Antihypertensive efficacy of metolazone
JP2005060359A (ja)	2005-03-10	血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用

Legal Events

Date	Code	Title	Description
2002-12-28	A201	Request for examination
2002-12-28	PA0105	International application	Patent event date: 20021228 Patent event code: PA01051R01D Comment text: International Patent Application
2002-12-28	PA0201	Request for examination
2003-06-18	PG1501	Laying open of application
2004-12-13	E902	Notification of reason for refusal
2004-12-13	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20041213 Patent event code: PE09021S01D
2005-05-02	E601	Decision to refuse application
2005-05-02	PE0601	Decision on rejection of patent	Patent event date: 20050502 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20041213 Comment text: Notification of reason for refusal Patent event code: PE06011S01I